Sonpavde, Guru
McMannis, John D.
Bai, Yu
Seethammagari, Mamatha R.
Bull, Joan M. C.
Hawkins, Victoria
Dancsak, Theresa K.
Lapteva, Natasha
Levitt, Jonathan M.
Moseley, Annemarie
Spencer, David M.
Slawin, Kevin M.
Funding for this research was provided by:
Bellicum Pharmaceuticals, Inc. (None)
Article History
Received: 7 August 2016
Accepted: 30 May 2017
First Online: 12 June 2017
Compliance with ethical standards
:
: G. Sonpavde: Consultant for Bayer, Sanofi, Pfizer, Novartis, Eisai, Janssen, Amgen, Astrazeneca, Merck, Genentech, Argos, Agensys; research support to institution from Bellicum, Bayer, Onyx, Celgene, Boehringer-Ingelheim, Merck, Pfizer; author for Uptodate; speaker for Clinical Care Options. J.D. McMannis, Y. Bai, M. Seethammagari, J.M.C. Bull, V. Hawkins, T. Dancsak, N. Lapteva, J.M. Levitt: funding to institution by Bellicum Pharmaceuticals, Inc. D.M. Spencer, A. Moseley, K.M. Slawin: employed by and shareholders of Bellicum Pharmaceuticals, Inc.
: The protocol was approved by the institutional review boards (IRBs) at the University of Texas, Houston, Texas.
: All participants provided written informed consent. The trial was registered at ClinicalTrials.gov under the identification NCT00868595.
: The trial was funded and sponsored by Bellicum Pharmaceuticals, Inc.